Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.44 |
| ▸ | GSR | P00390 | 2/20 | 0.42 |
| ▸ | GRM8 | O00222 | 1/20 | 0.42 |
| ▸ | GRM6 | O15303 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.42 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.42 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1769600 | 1.00 | OTC (0.44) | OTCGSRGRM8GRM6GRIN2D | |
| SCHEMBL2236138 | 0.90 | OTC (0.56) | OTCGSRGRM8GRM6GRIN2D | |
| SCHEMBL2236146 | 0.90 | OTC (0.56) | OTCGSRGRM8GRM6GRIN2D | |
| SCHEMBL1769657 | 0.84 | OTC (0.45) | OTCGSRGRM8GRM6GRIN2D | |
| SCHEMBL1769653 | 0.84 | OTC (0.45) | OTCGSRGRM8GRM6GRIN2D | |
| SCHEMBL1768536 | 0.82 | GFPT1 (0.40) | GSRGRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL1768532 | 0.82 | GFPT1 (0.40) | GSRGRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL2236892 | 0.80 | GSR (0.48) | OTCGSRGRM8GRM6GRIN2D | |
| SCHEMBL2236894 | 0.80 | GSR (0.48) | OTCGSRGRM8GRM6GRIN2D | |
| SCHEMBL2888856 | 0.79 | NOS2 (0.55) | GSRGRM8GRM6GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637520-B2 | Template-fixed peptidomimetics with CXCR7 modulating activity | POLYPHOR AG (CH) | 2017-05-02 | — | — | US | disclosed |
| EP-2531520-B1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | POLYPHOR AG (CH) | 2016-05-11 | — | — | EP | disclosed |
| US-20150307556-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | POLYPHOR AG (CH) | 2015-10-29 | — | — | US | disclosed |
| US-9109009-B2 | Template-fixed peptidomimetics with CXCR7 modulating activity | POLYPHOR AG (CH) | 2015-08-18 | — | — | US | disclosed |
| US-8754038-B2 | Template-fixed peptidomimetics with CCR10 antagonistic activity | POLYPHOR AG (CH) | 2014-06-17 | — | — | US | disclosed |
| US-20130225506-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | POLYPHOR AG (CH) | 2013-08-29 | — | — | US | disclosed |
| EP-2531520-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | Polyphor AG (CH) | 2012-12-12 | — | — | EP | disclosed |
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | POLYPHOR AG (CH) | 2012-11-08 | — | — | US | disclosed |
| WO-2011095607-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | POLYPHOR AG (CH) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011060832-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | POLYPHOR AG (CH) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | CCR10, CCR1, CCRL2 | OTC 4591/4885GSR 4018/4885GRM8 1650/4885 |
| US-20150307556-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | CXCR1, CXCL12, CXCR6 | OTC 3226/4885GSR 2525/4885GRM8 1081/4885 |
| US-20130225506-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | CXCR1, CXCL12, CXCR6 | OTC 3134/4885GSR 2635/4885GRM8 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.